Department of Infectious Disease, Nantong Third People's Hospital, Nantong 226006, Jiangsu Province, China.
World J Gastroenterol. 2021 Jul 7;27(25):3851-3862. doi: 10.3748/wjg.v27.i25.3851.
Gastric cancer (GC) is a common malignancy that results in a high rate of cancer-related mortality. Cisplatin (DDP)-based chemotherapy is the first-line clinical treatment for GC therapy, but chemotherapy resistance remains a severe clinical challenge. Zinc oxide nanoparticle (ZnO-NP) has been identified as a promising anti-cancer agent, but the function of ZnO-NP in GC development is still unclear.
To explore the effect of ZnO-NP on chemotherapy resistance during GC progression.
ZnO-NP was synthesized, and the effect and underlying mechanisms of ZnO-NP on the malignant progression and chemotherapy resistance of GC cells were analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, colony formation assays, transwell assays, wound healing assays, flow cytometry, and Western blot analysis in GC cells and DDP-resistant GC cells, and by tumorigenicity analyses in nude mice.
Our data revealed that ZnO-NP was able to inhibit proliferation, migration, and invasion and induce apoptosis of GC cells. Meanwhile, ZnO-NP significantly reduced the half maximal inhibitory concentration (IC) of DDP for the inhibition of cell proliferation of DDP-resistant SGC7901/DDP cell lines. Autophagy was increased in DDP-resistant GC cells, as demonstrated by elevated light chain 3-like protein 2 (LC3II)/LC3I and Beclin-1 expression and repressed p62 expression in SGC7901/DDP cells compared to SGC7901 cells. Mechanically, ZnO-NP inhibited autophagy in GC cells and treatment with DDP induced autophagy, which was reversed by ZnO-NP. Functionally, ZnO-NP attenuated the tumor growth of DDP-resistant GC cells .
We conclude that ZnO-NP alleviates the chemoresistance of GC cells by inhibiting autophagy. Our findings present novel insights into the mechanism by which ZnO-NP regulates the chemotherapy resistance of GC. ZnO-NP may serve as a potential therapeutic candidate for GC treatment. The potential role of ZnO-NP in the clinical treatment of GC needs clarification in future investigations.
胃癌(GC)是一种常见的恶性肿瘤,其导致的癌症相关死亡率较高。顺铂(DDP)为基础的化疗是 GC 治疗的一线临床治疗方法,但化疗耐药仍然是一个严重的临床挑战。氧化锌纳米粒子(ZnO-NP)已被确定为一种有前途的抗癌药物,但 ZnO-NP 在 GC 发展中的作用尚不清楚。
探讨 ZnO-NP 在 GC 进展过程中对化疗耐药性的影响。
合成 ZnO-NP,通过 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)测定、集落形成测定、transwell 测定、划痕愈合测定、流式细胞术和 Western blot 分析,研究 ZnO-NP 对 GC 细胞和 DDP 耐药 GC 细胞的恶性进展和化疗耐药性的影响,以及在裸鼠中的致瘤性分析。
我们的数据表明,ZnO-NP 能够抑制 GC 细胞的增殖、迁移和侵袭,并诱导其凋亡。同时,ZnO-NP 显著降低了 DDP 对 DDP 耐药 SGC7901/DDP 细胞系抑制细胞增殖的半抑制浓度(IC)。与 SGC7901 细胞相比,DDP 耐药 GC 细胞中的自噬增加,表现为 LC3II/LC3I 和 Beclin-1 表达升高,p62 表达降低。机制上,ZnO-NP 抑制 GC 细胞中的自噬,DDP 诱导自噬,而 ZnO-NP 可逆转这一过程。功能上,ZnO-NP 减弱了 DDP 耐药 GC 细胞的肿瘤生长。
我们得出结论,ZnO-NP 通过抑制自噬缓解 GC 细胞的化疗耐药性。我们的研究结果为 ZnO-NP 调节 GC 化疗耐药性的机制提供了新的见解。ZnO-NP 可能成为 GC 治疗的潜在治疗候选物。未来的研究需要阐明 ZnO-NP 在 GC 临床治疗中的潜在作用。